吡菲尼酮对牛血清蛋白诱导的肝纤维化大鼠肝损害的保护作用观察*

doi:10.3969/j.issn.1672-5069.2015.01.016

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (1): 63-66.doi: 10.3969/j.issn.1672-5069.2015.01.016

吡菲尼酮对牛血清蛋白诱导的肝纤维化大鼠肝损害的保护作用观察^*

李萍, 杨秋辉, 王俊岭, 江智龙

300192 天津市第二人民医院中西医结合二科/天津市肝病医学研究所（李萍）; 天津医科大学（杨秋辉,王俊岭）; 天津中医药大学（江智龙）

收稿日期:2014-07-14 出版日期:2015-12-17 发布日期:2015-12-17
作者简介:李萍,女,41岁,医学博士,主任医师。主要从事病毒性肝炎的诊断与治疗学研究。E-mail：tjlplxg@163.com
基金资助:
天津市卫生局（编号：06ky17）

Inhibition of hepatic fibrosis induced by bovine serum albumin by pirfenidone in rats

Li Ping, Yang Qiuhui, Wang Junling, et al

Second People's Hospital,Tianjin 301900,China

Received:2014-07-14 Online:2015-12-17 Published:2015-12-17

摘要/Abstract

摘要： 目的探讨吡菲尼酮对牛血清蛋白诱导的大鼠肝纤维化的影响。方法雄性Wistar大鼠30只被随机分为3组,给予模型组腹腔注射牛血清白蛋白,正常对照组接受等量的生理盐水腹腔注射,治疗组在腹腔注射牛血清白蛋白5 w后,按200 mg·kg^-1·d^-1灌胃给药吡菲尼酮,治疗4 w后处死试验动物,留取肝脏组织,行HE和Masson染色,观察肝脏病理学改变,采用免疫组化法检测Smad6蛋白表达。结果与模型组比,吡菲尼酮治疗组肝组织纤维化S3 和S4期病变较模型组明显减少,炎症细胞浸润明显减少,胶原纤维间隔缩小,着色变浅;模型组肝组织Smad6相对表达量为（108.2±33.6）,显著低于吡菲尼酮治疗组[（329.4±39.2）,P<0.05]。结论吡菲尼酮可抑制牛血清蛋白诱导的大鼠肝纤维化,其机制与通过上调Smad 6蛋白表达有关。

关键词: 肝纤维化, 吡菲尼酮, Smad6, 大鼠

Abstract: Objective To investigate the impact of pirfenidone on liver fibrosis induced by bovine serum albumin （BSA） in rats and its relevant mechanism. Methods 30 male Wistar rats were randomly divided into three groups: e.g. in control group the rats were given saline intraperitoneally,in model group were given BSA intraperitoneally,and in treatment group were given intragastric administration of pirfenidone at the dose of 200 mg.kg^-1.d^-1 after 5-week intraperitoneal injection of BSA. The animals were sacrificed after 4-week treatment and the liver specimens were collected. Hepatic pathology was performed by haematoxylin-eosin stain and Masson trichrome stain,and the expression of Smad 6 was detected by immunohistochemistry. Results As compared with in model group, the number of cases with liver fibrosis stage of S3-S4 in treatment group decreased, with significantly reduced infiltration of inflammatory cells,narrowed fibrous septum in liver tissues. Relative expression of Smad 6 in model group was significantly lower than that in treatment group [（108.2±33.6） vs. （329.4±39.2）,P<0.05]. Conclusions Pirfenidone can inhibit liver fibrosis induced by BSA in rats,which might be attributed to the upregulation of Smad 6.

Key words: Liver fibrosis, Pirfenidone, Smad6, Rats

李萍, 杨秋辉, 王俊岭, 江智龙. 吡菲尼酮对牛血清蛋白诱导的肝纤维化大鼠肝损害的保护作用观察^*[J]. 实用肝脏病杂志, 2015, 18(1): 63-66.

Li Ping, Yang Qiuhui, Wang Junling, et al. Inhibition of hepatic fibrosis induced by bovine serum albumin by pirfenidone in rats[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 63-66.

参考文献

[1] Salazar-Montes A,Ruiz-Corro L,Lopez-Reyes A,et al.Potent antioxidant role of pirfenidone in experimental cirrhosis,Eur J Pharmacol,2008,595（1-3）：69-77.
[2] Takeda Y,Tsujino K,Kijima T,et al.Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence,2014,8：361-370.
[3] Conte E,Gili E,Fagone E,et al.Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.Eur J Pharm Sci,2014,58C：13-19.
[4] 唐桂连. 肝星状细胞与肝纤维化.国际消化病杂志,2012,13（5）：270-273.
[5] 王美玲,陆伦根.肝纤维化治疗研究进展.实用肝脏病杂志,2013,16（4）：369-371.
[6] 李旭,齐明华.肝内细胞上皮-间质转化:肝纤维化发生的新机制.世界华人消化杂志,2012,15（10）：811-817.
[7] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,6（6）：324-329.
[8] 陈月桥,毛德文.肝纤维化动物模型制备的研究进展.实用肝脏病杂志,2007,10（3）：205-207.
[9] Di Sario A,Bendia E,Macarri G,et al.The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1（I）,TIMP-1 and MMP-2.Dig Liver Dis,2004,36（11）：744-751.
[10] 李紫琼,郑勇. TIMPs和MMPs与肝纤维化研究进展. 实用肝脏病杂志,2007,10（5）：355-358.
[11] Di Sario A,Bendia E,Svegliati BG,et al.Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production,J Hepatol,2002,37（5）：584-591.
[12] Kaibori M,Yanagida H,Uchida Y,et al.Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats.Transplant Proc,2004,36（7）：1973-1974.
[13] Wang F,Wen T,Chen X Y,et al.Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats.Inflamm Res,2008,57（4）：183-188.
[14] 李萍,陶立坚,胡国龄,等.1-（3-氟苯基）-5-甲基-2-（1H）吡啶酮对肝星状细胞的影响.中国临床药理学与治疗学,2007,18（7）：782-785.
[15] Lim Y S,Lee H S.The expression of E-cadherin in human and rat hepatic stellate cells:evidence of epithelial-mesenchymal transition.Taehan Kan Hakhoe Chi,2002,8（1）：90-99.
[16] Li Y,Sun Y,Liu F,et al.Correction: norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition. PLoS One,2013,8（10）:e44324.
[17] Srivastava S P,Koya D,Kanasaki K. MicroRNAs in kidney fibrosis and diabetic nephropathy:roles on EMT and EndMT. Biomed Res Int,2013,20（13）：125469.
[18] Desmouliere A,Darby I A,Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest,2003,83（12）：1689-1707.
[19] Zeisberg M,Hanai J,Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med,2003,9（7）：964-968.
[20] Bi WR,Xu GT,Lv LX,et al. The ratio of transforming growth factor-beta1/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis.Genet Mol Res,2014,13（1）：1005-1014.

吡菲尼酮对牛血清蛋白诱导的肝纤维化大鼠肝损害的保护作用观察^*

Inhibition of hepatic fibrosis induced by bovine serum albumin by pirfenidone in rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[3]	高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[7]	林秋香, 王雪雯, 黄祖雄, 潘晨. 灯盏花素对肝脏缺血再灌注损伤大鼠肝脏和肠黏膜屏障功能的保护作用*[J]. 实用肝脏病杂志, 2019, 22(5): 636-639.
[8]	石小龙, 杜睿, 秦革萍, 薛华燕, 张宏鑫. 七氟醚对脓毒症大鼠肝损伤的保护作用及其作用机制研究*[J]. 实用肝脏病杂志, 2019, 22(5): 640-643.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	王艳, 苏峰, 李园园, 李舒. 蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 474-477.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[14]	周丽云, 李校天, 李丽, 杨俊超. 1,25（OH）₂D₃通过调节miR-146a水平抑制大鼠肝纤维化的体内和体外观察[J]. 实用肝脏病杂志, 2019, 22(3): 333-336.
[15]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.